OCGN
VENTE TOTALE: 468 727 titres (~524 974,24 $ US)
- Insiders
- Musunuri Shankar
- Total bought
- —
- Total sold
- $524,974
- Last activity
- 2026-09-09
- Last synced
-
2026-09-13 10:23:38
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-12
OCGN presents a deeply distressed financial profile with near-critical liquidity (current ratio collapsed to 1.05), persistent negative cash flows, and no meaningful catalytic event to justify near-term re-rating.
The first sentence of the analysis written for OCGN on 2026-09-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 45.9% | 51.5% | 88.3% | 100.0% | 0.0% | |
| Ebit Margin | -1419.9% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Ebitda Margin | -1365.7% | -1284.5% | -1033.4% | -3469.6% | 0.0% | |
| Operating Profit Margin | -1425.7% | -1350.4% | -1085.7% | -3580.0% | 0.0% | |
| Pretax Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Continuous Operations Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Net Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Bottom Line Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Current Ratio | 1.056 | 2.857 | 2.515 | 3.452 | 14.664 | |
| Quick Ratio | 1.056 | 2.857 | 2.515 | 3.452 | 14.664 | |
| Solvency Ratio | -1.176 | -0.986 | -2.601 | -2.491 | -5.847 | |
| Cash Ratio | 0.806 | 2.710 | 2.309 | 2.719 | 13.565 | |
| Price To Earnings Ratio | -5.870 | -4.025 | -2.212 | -3.250 | -15.167 | |
| Price To Earnings Growth Ratio | -0.391 | 0.174 | 0.063 | -0.097 | 4.702 | |
| Forward Price To Earnings Growth Ratio | -0.391 | 0.174 | 0.063 | -0.097 | 4.702 | |
| Price To Earnings Diluted Ratio | -5.870 | -4.025 | -2.212 | -3.250 | -15.167 | |
| Price To Earnings Diluted Growth Ratio | -0.391 | 0.174 | 0.063 | -0.097 | 4.702 | |
| Price To Book Ratio | -33.308 | 7.362 | 3.463 | 3.771 | 9.260 | |
| Price To Sales Ratio | 91.826 | 53.798 | 23.275 | 112.130 | 0.000 | |
| Price To Free Cash Flow Ratio | -7.091 | -4.792 | -1.937 | -4.323 | -18.153 | |
| Price To Operating Cash Flow Ratio | -7.114 | -5.177 | -2.264 | -4.644 | -18.508 | |
| Debt To Assets Ratio | 0.762 | 0.394 | 0.108 | 0.059 | 0.031 | |
| Debt To Equity Ratio | -2.724 | 1.097 | 0.171 | 0.086 | 0.035 | |
| Debt To Capital Ratio | 1.580 | 0.523 | 0.146 | 0.079 | 0.033 | |
| Long Term Debt To Capital Ratio | 1.791 | 0.480 | 0.065 | 0.030 | 0.018 | |
| Financial Leverage Ratio | -3.577 | 2.782 | 1.591 | 1.468 | 1.104 | |
| Working Capital Turnover Ratio | 0.213 | 0.123 | 0.126 | 0.030 | 0.000 | |
| Operating Cash Flow Ratio | -2.472 | -1.952 | -3.631 | -2.106 | -6.849 | |
| Operating Cash Flow Sales Ratio | -12.908 | -10.393 | -10.281 | -24.148 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.080 | 1.169 | 1.074 | 1.020 | |
| Debt Service Coverage Ratio | -9.361 | -39.281 | 0.000 | 0.000 | -734.899 | |
| Interest Coverage Ratio | -12.127 | 0.000 | 0.000 | 0.000 | -734.532 | |
| Short Term Operating Cash Flow Coverage Ratio | -45.571 | -31.781 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.719 | -1.297 | -8.940 | -9.426 | -14.501 | |
| Capital Expenditure Coverage Ratio | -307.914 | -12.450 | -5.923 | -13.480 | -51.055 | |
| Dividend Paid And Capex Coverage Ratio | -307.914 | -12.450 | -5.923 | -13.480 | -51.055 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.965 | -3.689 | -1.731 | -2.407 | -13.692 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 45.9% | ▼-5.6% | ▼-11.3% |
| Ebit Margin | -1419.8% | ▼-86.8% | ▲37.5% |
| Ebitda Margin | -1365.7% | ▼-81.2% | ▲64.9% |
| Operating Profit Margin | -1425.7% | ▼-75.3% | ▲62.6% |
| Pretax Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Continuous Operations Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Net Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Bottom Line Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Current Ratio | 1.056 | ▼-1.801 | ▼-3.853 |
| Quick Ratio | 1.056 | ▼-1.801 | ▼-3.853 |
| Solvency Ratio | -1.176 | ▼-0.189 | ▲1.445 |
| Cash Ratio | 0.806 | ▼-1.905 | ▼-3.616 |
| Price To Earnings Ratio | -5.870 | ▼-1.845 | ▲0.235 |
| Price To Earnings Growth Ratio | -0.391 | ▼-0.566 | ▼-1.281 |
| Forward Price To Earnings Growth Ratio | -0.391 | ▼-0.566 | ▼-1.281 |
| Price To Earnings Diluted Ratio | -5.870 | ▼-1.845 | ▲0.235 |
| Price To Earnings Diluted Growth Ratio | -0.391 | ▼-0.566 | ▼-1.281 |
| Price To Book Ratio | -33.308 | ▼-40.670 | ▼-31.418 |
| Price To Sales Ratio | 91.826 | ▲38.028 | ▲35.620 |
| Price To Free Cash Flow Ratio | -7.091 | ▼-2.299 | ▲0.168 |
| Price To Operating Cash Flow Ratio | -7.114 | ▼-1.937 | ▲0.427 |
| Debt To Assets Ratio | 0.762 | ▲0.367 | ▲0.491 |
| Debt To Equity Ratio | -2.724 | ▼-3.821 | ▼-2.457 |
| Debt To Capital Ratio | 1.580 | ▲1.057 | ▲1.108 |
| Long Term Debt To Capital Ratio | 1.791 | ▲1.311 | ▲1.315 |
| Financial Leverage Ratio | -3.577 | ▼-6.359 | ▼-4.251 |
| Working Capital Turnover Ratio | 0.213 | ▲0.090 | ▲0.115 |
| Operating Cash Flow Ratio | -2.472 | ▼-0.520 | ▲0.930 |
| Operating Cash Flow Sales Ratio | -12.908 | ▼-2.516 | ▼-1.362 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▼-0.077 | ▼-0.066 |
| Debt Service Coverage Ratio | -9.361 | ▲29.919 | ▲147.347 |
| Interest Coverage Ratio | -12.127 | ▼-12.127 | ▲137.205 |
| Short Term Operating Cash Flow Coverage Ratio | -45.571 | ▼-13.790 | ▼-30.101 |
| Operating Cash Flow Coverage Ratio | -1.719 | ▼-0.422 | ▲5.458 |
| Capital Expenditure Coverage Ratio | -307.913 | ▼-295.464 | ▼-229.749 |
| Dividend Paid And Capex Coverage Ratio | -307.913 | ▼-295.464 | ▼-229.749 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.965 | ▼-3.276 | ▼-1.268 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $405.2M | $218.2M | $140.5M | $279.0M | $887.3M | |
| Enterprise value | $419.8M | $192.1M | $108.0M | $207.8M | $795.7M | |
| EV / Sales | 95.13x | 47.38x | 17.89x | 83.52x | 0.00x | |
| EV / Op. cash flow | -7.37x | -4.56x | -1.74x | -3.46x | -16.60x | |
| EV / Free cash flow | -7.35x | -4.22x | -1.49x | -3.22x | -16.28x | |
| EV / EBITDA | -6.96x | -3.69x | -1.73x | -2.41x | -13.69x | |
| Net debt / EBITDA | -0.24x | 0.50x | 0.52x | 0.82x | 1.58x | |
| Current ratio | 1.06x | 2.86x | 2.52x | 3.45x | 14.66x | |
| Income quality | 0.84x | 0.78x | 0.98x | 0.69x | 0.82x | |
| Graham net-net | -$0 | $0 | $0 | $0 | $0 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 99.9% | |
| Interest burden | 108.3% | 100.0% | 100.0% | 100.0% | 100.1% | |
| Working capital | $1.3M | $40.1M | $25.9M | $70.0M | $95.6M | |
| Invested capital | $15.7M | $56.6M | $43.2M | $76.0M | $96.8M | |
| Return on assets | -155.9% | -65.6% | -97.7% | -79.9% | -55.2% | |
| Operating ROA | -99.9% | -74.5% | -75.7% | -83.1% | -87.2% | |
| Return on tangible assets | -155.9% | -65.6% | -97.7% | -79.9% | -55.2% | |
| Return on equity | 557.7% | -182.4% | -155.5% | -117.3% | -60.9% | |
| Return on invested capital | -278.6% | -87.3% | -136.4% | -110.5% | -58.5% | |
| Return on capital employed | -307.3% | -90.0% | -138.1% | -111.2% | -58.8% | |
| Earnings yield | -16.7% | -24.8% | -44.9% | -31.1% | -6.6% | |
| Free cash flow yield | -14.1% | -20.9% | -51.6% | -23.1% | -5.5% | |
| Capex / Op. cash flow | -0.3% | -8.0% | -16.9% | -7.4% | -2.0% | |
| Capex / Depreciation | 7.7% | 172.0% | 1488.1% | 928.5% | 410.0% | |
| Capex / Sales | 4.2% | 83.5% | 173.6% | 179.1% | 0.0% | |
| SG&A / Sales | 624.9% | 658.1% | 530.1% | 1422.8% | 0.0% | |
| R&D / Sales | 900.7% | 792.3% | 655.6% | 2257.2% | 0.0% | |
| Stock comp / Sales | 174.6% | 183.2% | 152.7% | 423.7% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 948d | 787d | 1645d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -948d | -787d | -1645d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+85.8%EV / Sales ▲+100.8%EV / EBITDA ▼-88.8%EV / Op. cash flow ▼-2.810Earnings yield ▲+0.080
Profitability
Return on equity ▲+7.401Return on assets ▼-0.903Return on invested capital ▼-1.913Return on capital employed ▼-2.173Operating ROA ▼-0.254Income quality ▲+0.060Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+160.625Operating cycle n/aCash conversion cycle ▼-160.625Capex / Sales ▼-0.793R&D / Sales ▲+1.085
Balance-sheet strength
Current ratio ▼-1.801Net debt / EBITDA ▼-0.741Working capital ▼-38797000.000Invested capital ▼-40959000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-54.3%EV / Sales n/aEV / EBITDA ▲+49.1%EV / Op. cash flow ▲+9.227Earnings yield ▼-0.102
Profitability
Return on equity ▲+6.186Return on assets ▼-1.007Return on invested capital ▼-2.201Return on capital employed ▼-2.486Operating ROA ▼-0.127Income quality ▲+0.018Tax burden ▲+0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-13.607Net debt / EBITDA ▼-1.819Working capital ▼-94349000.000Invested capital ▼-81121000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-11-07 | Chris Jacobs | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-09-11 Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.
- 2026-09-02 OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
- 2026-09-01 Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.
- 2026-08-25 Ocugen to Participate in Upcoming September Investor and Industry Conferences MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.
- 2026-08-17 Brokerages Set Ocugen, Inc. (NASDAQ:OCGN) Price Target at $9.50 Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month
- 2026-08-15 Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
- 2026-08-07 Ocugen''s Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
- 2026-08-07 Ocugen Q2 Earnings Call Highlights Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
- 2026-08-06 Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
- 2026-08-06 Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.